Implantable Headwinds Clip Alcon Revenue Pace Despite Solid Premium Lens Gains

Alcon Inc. (NYSE:ALC) reported third-quarter adjusted earnings of 91 cents per share, beating the consensus estimate of 87 cents. Sales increased 5% year over year to $2.717 billion, missing the Wall Street estimate of $2.737 billion.

Segment Breakdown: Implantables, Consumables and Contact Lenses

Implantables net sales were $422 million, down 2%, reflecting a decrease in IOLs of 1% constant currency, driven primarily by competitive launches in the U.S. premium IOL category and continued reimbursement challenges for dual procedures in glaucoma implants.

Consumables net sales rose 6% to $789 million, driven by procedural volumes, price increases, and Valeda consumables.

Contact lenses net sales were $737 million, up 4%, reflecting a favorable mix of premium products as well as price increases, particularly in the U.S., and were partially offset by declines in legacy products.

Executive Commentary on Market Trends and IOL Competition

Alcon CEO David Endicott said, “In the U.S., competitive trialing and sampling of IOLs remain significant, and we expect that activity to continue through the early part of next year. At the same time, we are strengthening our competitive position with the next wave of innovation in our IOL portfolio.”

On the earnings call, Endicott said, “Although mix remains positive across markets, the important trend is continued premiumization as consumers move toward daily disposables and specialty lenses.”

“That shift supports positive mix and plays directly to the strength of our portfolio in these higher-valued categories. In cataract procedures, growth remains in line with our assumptions and below historical levels, reflecting capacity constraints in the U.S. and reimbursement and hospital economics internationally,” Endicott commented.

Updated Fiscal 2026 Guidance and Analyst Expectations

Alcon narrowed its fiscal 2026 adjusted earnings guidance to $3.44 to $3.50 per share, from $3.44 to $3.53, compared with the Street estimate of $3.44.

The company narrowed its 2026 sales guidance to $10.938 billion, from $10.835 billion to $11.041 billion, versus the consensus estimate of $11.073 billion.

Needham wrote that while product momentum continues to drive growth, the underlying market remains on the softer side, resulting in guidance assuming the lower end of 3% market growth for the year.

Needham analyst David Saxon reiterated a Buy rating and a price forecast of $98.

ALC Price Action: Alcon shares were down 2.98% at $71.85 at the time of publication Wednesday, according to Benzinga Pro data.

Photo: Shutterstock